NovaBridge Biosciences (NBP) names officer Hagler Mark Arnold in Form 3

Rhea-AI Filing Summary

NovaBridge Biosciences filed an initial Form 3 for Hagler Mark Arnold, who is identified as an officer of the company with the title noted as “See Remarks.” The filing does not report any transactions or holdings, serving as an initial beneficial ownership statement.

Key Terms

Form 3, officer, beneficial ownership

3 terms

Form 3 regulatory

"NovaBridge Biosciences filed an initial Form 3 for Hagler Mark Arnold"

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

officer financial

"Hagler Mark Arnold is identified as an officer of the company"

beneficial ownership financial

"serving as an initial beneficial ownership statement"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

Understanding Insider Trading Forms →

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Hagler Mark Arnold

(Last) (First) (Middle)

C/O NOVABRIDGE BIOSCIENCES,

2440 RESEARCH BOULEVARD, SUITE 400

(Street)

ROCKVILLE MARYLAND 20850

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
04/17/2026

3. Issuer Name and Ticker or Trading Symbol
NovaBridge Biosciences [ NBP ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

President and Chief Commercial Officer Exhibit List: Ex. 24.1 - Power of Attorney

No securities are beneficially owned.

	/s/ Xi-Yong (Sean) Fu as attorney-in-fact	04/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does the NovaBridge Biosciences (NBP) Form 3 for Hagler Mark Arnold show?

The Form 3 shows that Hagler Mark Arnold is an officer of NovaBridge Biosciences. It functions as his initial beneficial ownership statement and does not list any specific transactions or share holdings in the data provided.

Are there any stock transactions reported for Hagler Mark Arnold in this NovaBridge Biosciences (NBP) Form 3?

No transactions are reported in this Form 3. The transaction summary shows zero buys, sells, exercises, gifts, tax withholdings, or restructurings, indicating only an initial reporting status without trading activity disclosed.

Does the NovaBridge Biosciences (NBP) Form 3 indicate Hagler Mark Arnold is a 10% owner?

The Form 3 data indicates Hagler Mark Arnold is not a ten percent owner. He is classified as an officer, with the officer title specified as “See Remarks,” and the ten percent owner flag is set to zero in the filing details.

What derivative positions are disclosed for Hagler Mark Arnold in the NovaBridge Biosciences (NBP) Form 3?

The Form 3 shows no derivative positions for Hagler Mark Arnold. The derivative summary is empty, and the transaction summary lists zero derivative transactions or exercises, so no options or similar instruments are detailed here.

Does the NovaBridge Biosciences (NBP) Form 3 include any footnote-based ownership disclaimers?

The Form 3 includes a footnotes section, but only a null entry appears in the provided data. As shown, there are no specific explanatory or disclaimer footnotes about Hagler Mark Arnold’s voting or investment authority disclosed here.